Search results: Sage Journals

Free accessResearch articleFirst published May, 2018

Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer

Pilei Si, Ye Xu, Tao Ouyang [...]

Cancer Biomarkers

Open accessResearch articleFirst published 2018

Frequency,impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer

Naomi Elster, Sinead Toomey, Yue Fan [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2026

Economic Evaluation of Inavolisib Combined With Palbociclib–Fulvestrant for PIK3CA-Mutated,HR+/HER2− Advanced Breast Cancer in USA

Hanqing Zeng, Li-Ying Song, Ren Guo [...]

Technology in Cancer Research & Treatment

Open accessResearch articleFirst published 2025

Combination regimens as potential treatment of non-small-cell lung cancer patients with HER2 mutation in the real world: a multicenter study

Yue Hao, Qian Wang, Ke Wang [...]

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published May, 2025

Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC),Especially in China

Chang Liu, Tao Li, Xiaoran Cui [...]

Cancer Control

Open accessCase reportFirst published 2021

Olaparib in hormone receptor-positive,HER2-negative metastatic breast cancer with a somatic BRCA2 mutation

Lee S. Schwartzberg, Lesli A. Kiedrowski

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2024

HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis

Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published 2025

Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated,HR-positive,HER2-negative invasive breast cancer: A systematic review

Chris Larck, Joseph B Elmes, R. Wesley Haynes [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2021

Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1 / 2 mutations and hormone receptor status from the phase-3 BROCADE3 trial

Jean-Pierre Ayoub, Hans Wildiers, Michael Friedlander [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2026

Comprehensive genomic landscape of ERBB2 in Chinese GI tumors: mutation-centered landscapes and precision treatment opportunities

Yinan Shi, Xiaoxuan Wang, Xiaotong Xi [...]

Therapeutic Advances in Medical Oncology

Free accessResearch articleFirst published May, 2018

Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer

Pilei Si, Ye Xu, Tao Ouyang [...]

Cancer Biomarkers

Open accessResearch articleFirst published 2018

Frequency,impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer

Naomi Elster, Sinead Toomey, Yue Fan [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2026

Economic Evaluation of Inavolisib Combined With Palbociclib–Fulvestrant for PIK3CA-Mutated,HR+/HER2− Advanced Breast Cancer in USA

Hanqing Zeng, Li-Ying Song, Ren Guo [...]

Technology in Cancer Research & Treatment

Open accessResearch articleFirst published 2025

Combination regimens as potential treatment of non-small-cell lung cancer patients with HER2 mutation in the real world: a multicenter study

Yue Hao, Qian Wang, Ke Wang [...]

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published May, 2025

Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC),Especially in China

Chang Liu, Tao Li, Xiaoran Cui [...]

Cancer Control

Open accessCase reportFirst published 2021

Olaparib in hormone receptor-positive,HER2-negative metastatic breast cancer with a somatic BRCA2 mutation

Lee S. Schwartzberg, Lesli A. Kiedrowski

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2024

HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis

Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published 2025

Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated,HR-positive,HER2-negative invasive breast cancer: A systematic review

Chris Larck, Joseph B Elmes, R. Wesley Haynes [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2021

Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1 / 2 mutations and hormone receptor status from the phase-3 BROCADE3 trial

Jean-Pierre Ayoub, Hans Wildiers, Michael Friedlander [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2026

Comprehensive genomic landscape of ERBB2 in Chinese GI tumors: mutation-centered landscapes and precision treatment opportunities

Yinan Shi, Xiaoxuan Wang, Xiaotong Xi [...]

Therapeutic Advances in Medical Oncology